Posted by Michael Wonder on 11 Feb 2019
Regeneron and Sanofi offer Praluent (alirocumab) at a new reduced U.S. list price
11 February 2019 - This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients.
Regeneron Pharmaceuticals and Sanofi today announced that Praluent (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March.
The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Regeneron and Sanofi committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.
